PDLI Projected Dividend Yield

PDL BioPharma Inc ( NASDAQ : PDLI )

PDL BioPharma is engaged in providing alternative sources of capital through royalty monetizations and debt facilities; acquiring commercial-stage products and launching companies for commercialization of these products; as well as transactions involving late clinical-stage or early commercial-stage therapeutics. Co.'s subsidiary, LENSAR, Inc., is a medical device company focused on delivering femtosecond cataract laser technology used in refractive cataract surgical procedures. Co. also has investment in Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health.

26 YEAR PERFORMANCE RESULTS